EMT抑制剂-1 | 1638526-21-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: EMT抑制剂-1
• 英文名称: 4-((4-(3,4-dichlorophenyl)-1,2,5-thiadiazol-3-yl)oxy)butan-1-ol
• 英文别名: EMT inhibitor-1；4-[[4-(3,4-dichlorophenyl)-1,2,5-thiadiazol-3-yl]oxy]butan-1-ol
• CAS: 1638526-21-2
• 化学式: C₁₂H₁₂Cl₂N₂O₂S
• 分子量: 319.211
• InChiKey: FWMUIOJZHOPPDX-UHFFFAOYSA-N

物化性质

• 沸点：
  443.3±45.0 °C(Predicted)
• 密度：
  1.415±0.06 g/cm3(Predicted)
• 溶解度：
  二甲基亚砜：≥ 5.6 mg/mL（17.54 mM）

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  83.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3,4-二氯苯甲醛 在 sulfur monochloride 、 sodium hydride 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 57.0h， 生成 EMT抑制剂-1
  参考文献：
  名称：

  [EN] INHIBITION OF WNT, TGF BETA AND HIPPO SIGNALING PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS
  [FR] INHIBITION DE VOIES DE SIGNALISATION DE WNT, DE TGF BÊTA ET HIPPO POUR TRAITER LE CANCER, LA FIBROSE D'ORGANES ET LES TROUBLES MÉTABOLIQUES

  摘要：

  公开号：

  WO2015031109A8

文献信息

• INHIBITION OF WNT, TGF BETA AND HIPPO SIGNALING PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS
  申请人：UNIVERSITY OF PITTSBURGH-OF THE COMMON WEALTH SYSTEM OF HIGHER EDUCATION

  公开号：US20160200697A1

  公开（公告）日：2016-07-14

  Compounds, or pharmaceutically acceptable salts or esters thereof, having a structure of: wherein each of R 1 -R 5 is individually selected from H, halogen, optionally substituted alkyl, optionally substituted alkoxy, nitro, sulfonamide, hydroxy, or amino; and R 6 is selected from H, optionally substituted alkyl, or optionally substituted aryl.

  化合物，或其药学上可接受的盐或酯，其结构为：其中R1-R5中的每个都是独立选择自H，卤素，可选取代烷基，可选取代烷氧基，硝基，磺酰胺基，羟基或氨基; 而R6则选择自H，可选取代烷基或可选取代芳基。
• Methods of treating resistant cancers
  申请人：University of Maryland, Baltimore

  公开号：US11246856B2

  公开（公告）日：2022-02-15

  Provided herein is a method for reducing resistance in an individual having a drug resistant cancer, for example, a BRAF inhibitor resistant cancer. A Hippo signaling pathway inhibitor such as a Yes-associated protein 1 (YAP1) inhibitor, a Transcriptional Coactivator with PDZ-binding motif (TAZ) inhibitor, a Transcription enhancer domain (TEAD) inhibitor or a combination of these is administered. Also provided is a method of treating BRAF inhibitor resistance in an individual with a BRAF inhibitor resistant cancer, for example, malignant melanoma, with a Hippo signaling pathway inhibitor, such as Verteporfin, and a BRAF inhibitor.

  本文提供了一种降低耐药性癌症（例如对 BRAF 抑制剂耐药的癌症）患者耐药性的方法。施用希波信号通路抑制剂，如是相关蛋白 1（YAP1）抑制剂、具有 PDZ 结合基调的转录激活子（TAZ）抑制剂、转录增强子结构域（TEAD）抑制剂或这些抑制剂的组合。还提供了一种治疗 BRAF 抑制剂耐药性癌症（例如恶性黑色素瘤）患者的 BRAF 抑制剂耐药性的方法，使用 Hippo 信号通路抑制剂（例如 Verteporfin）和 BRAF 抑制剂。
• Methods of Treating Resistant Cancers
  申请人：University of Maryland, Baltimore

  公开号：US20200147047A1

  公开（公告）日：2020-05-14

  Provided herein is a method for reducing resistance in an individual having a drug resistant cancer, for example, a BRAF inhibitor resistant cancer. A Hippo signaling pathway inhibitor such as a Yes-associated protein 1 (YAP1) inhibitor, a Transcriptional Coactivator with PDZ-binding motif (TAZ) inhibitor, a Transcription enhancer domain (TEAD) inhibitor or a combination of these is administered. Also provided is a method of treating BRAF inhibitor resistance in an individual with a BRAF inhibitor resistant cancer, for example, malignant melanoma, with a Hippo signaling pathway inhibitor, such as Verteporfin, and a BRAF inhibitor.
• US9649300B2
  申请人：——

  公开号：US9649300B2

  公开（公告）日：2017-05-16
• [EN] METHODS OF TREATING RESISTANT CANCERS<br/>[FR] MÉTHODES DE TRAITEMENT DE CANCERS RÉSISTANTS
  申请人：UNIV MARYLAND

  公开号：WO2018213748A1

  公开（公告）日：2018-11-22

  Provided herein is a method for reducing resistance in an individual having a drug resistant cancer, for example, a BRAF inhibitor resistant cancer. A Hippo signaling pathway inhibitor such as a Yes-associated protein 1 (YAP1 ) inhibitor, a Transcriptional Coactivator with PDZ-binding motif (TAZ) inhibitor, a Transcription enhancer domain (TEAD) inhibitor or a combination of these is administered. Also provided is a method of treating BRAF inhibitor resistance in an individual with a BRAF inhibitor resistant cancer, for example, malignant melanoma, with a Hippo signaling pathway inhibitor, such as Verteporfin, and a BRAF inhibitor.